Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 323-331

  Lee, Yun Sil ^a   Chung, I N Sung ^a   Lee, Ihn Rhan ^b   Kim, K I Hwan ^a,b   Hong, Weon Seon ^c   Yun, Yeon Sook ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Ewha Womans University   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

Antineoplastic; Immunostimulator; Non toxic; Panax ginseng; Polysaccharide

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BENZO[A]PYRENE; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 2; POLYSACCHARIDE; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACCESSORY CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PURIFICATION; FEMALE; GINSENG; IMMUNOSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; KILLER CELL; LUNG TUMOR; LYMPHOCYTE PROLIFERATION; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAXIMUM PERMISSIBLE DOSE; MELANOMA B16; MOLECULAR WEIGHT; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; IMMUNOPHENOTYPING; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PANAX; PLANTS, MEDICINAL; POLYSACCHARIDES;

EID: 0031057118     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lotze MT, Grimm EA, Mazumder A, Strausser JL and Rosenberg SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420-4425, 1981.
2. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon, lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823-1841, 1982.
3. Rosenstein M, Yron I, Kaufman Y and Rosenberg SA: Lymphokine-activated killer cells: Lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocyte cultured in interleukin 2, Cancer Res 44: 1946-1953, 1984.
4. Rosenberg SA, Loze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM: Observations of the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
5. West WH, Tuner KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB and Oldham RK: Consistant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898-905, 1987.
6. Rosenstein M, Ettinghaussen SE and Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735-1742, 1986.
7. Lotze, MT, Matory L, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA and Rosenberg SA: Clinical effects and toxicity of interleukin 2 in patients with cancer. Cancer Res 58: 2764-2772, 1986.
8. Itoh K, Shiba K, Shimizu Y, Suzuki R and Kumagai K: Generation of activated killer (AK) cells by recombinant interleukin-2(rlL2) in collaboration with Interferon γ (INFγ). J Immunol 134: 3124-3129, 1985.
9. Owen-Schaub LB, Gutterman JU and Grimm EA: Synergy of tumor necrosis factor α and interleukin 2 in the activation of human cytotoxic lymphocytes; Effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48: 788-792, 1989.
10. Crump III WL, Owen-Schaub LB and Grimm EA: Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res 49: 149-153, 1989.
11. Cameron RJ, McIntosh JK and Rosenberg SA: Synergistic antitumor effect of combination immunotherapy with recombinant interleukin 2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastasis. Cancer Res 48: 5810-5817, 1988.
12. von Rohr A, Ghosh AK, Thatcher N and Stern PL: Immuno-modulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer 67: 163-171, 1993.
13. Mironova AI: The influence of root extracts of ginseng and eleutherococcus on the growth of Ehrlich carcinoma. Vopr Onkol, 9: 42-44, 1963
14. Lee KD and Huemer RP: Antitumoral activity of Panax ginseng extracts. Jpn J Pharmacol 21: 299-301, 1971.
15. Yun TK, Yun YS and Han IW: Anticarcinogenic effect of long-term Oral administration of red ginseng on newborn mice exposed to various chemical carcinogens. Cancer Detct Prev 6: 515-525, 1983.
16. Yun TK and Lee YS: Trial of a new medium-term model using benzo(a)pyrene induced lung tumor in newborn mice. Anticancer Res 15: 839-836, 1995.
17. Yun TK and Choi SY: A case-control study of ginseng intake and cancer. Int J Epidemiol 19: 871-875, 1990.
18. Yun YS, Lee YS, Jo SK and Jung IS: Inhibition of autochthonous tumor by ethanol insoluble fraction from Panax ginseng as an immunomodulator. Planta Med 59: 521-524, 1993.
19. Ceredig R, Lowenthal JW, Nabholz M and MacDonald HR: Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature 314: 98-100, 1985.
20. Yun, YS, Hargrove ME and Ting CC: Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody. J Immunol 141: 1390-1397, 1988.
21. Ding AH, Nathan CF and Stuehr DJ: Release of reactive nitrogen intermediates and reactive oxgen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412, 1988.
22. Mule JJ and Rosenberg SA: Measurement of cytotoxic activity of LAK/NK cells. In: J.E. Coligan, A.M. Kruisbeek, D.H., Margalies, E.M. Shevach, and W. Strober (eds), Current protocols in immunology, PP. 7.18.1-7.18.7. New York: John Willey and Sons, 1991.
23. 3H]thymidine release In: H.B. Herscowitz, H.T. Holden, J.A. Bellanti, and A. Ghaffer(eds), Manual of macrophage methodology, PP. 329-336. New York: Marcel-Dekker, 1981.
24. Wimer BM: The ideal biological response modifier. Mol Biother 1: 311-317, 1989.
25. Scheurich P, Thoma B, Ucer U and Pfizenmaier K: Immune-regulatory activity of recombinant human tumor necrosis factor (TNF)-α: Induction of TNF receptors on human T cells and TNFα-mediated enhancement of T cell responses. J Immunol 138: 1786-1790, 1987.
26. Ostensen ME, Thiele DL and Lipsky PE: Tumor necrosis factor-α enhances cytolytic activity of human natural killer cells. J Immunol 138: 4185-4191, 1987.
27. 2 secretion in Hodgkin's disease and it's relation to decreased cellular immunity. Clin Exp Immunol 51: 61-68, 1983.
28. Lanier LL, Benike CJ, Philips JH and Engleman EG: Recombinant interleukin. 2 enhanced natural cell mediated cytotoxicity in human lymphocyte subpopulations expressing the LEU7 and LEU11 antigens. J Immunol 134: 794-801, 1985.
29. Ortaldo JR, Mason A and Overton R: Lymphokine activated killer cells: Analysis of progenitors and effectors. J Exp Med 164: 1193-1205, 1986.
30. Yang JC, Mule JJ and Rosenberg SA: Murine lymphocyte-activated killer (LAK) cells: Phenotypic characterization of the precursor and effector cells. J Immunol 137: 715-722, 1986.
31. Silvennoinen O, Vakkila J and Hurme M: Accessory cells, dendritic cells, or monocytes are required for the lymphokine activated killer cell induction from resting T cell but not from natural killer cell precursors. J Immunol 141: 1404-1409, 1988.
32. Maghazachi AA, Herberman RB, Vujanovic NL and Hiserodt JC: In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. Cell Immunol 115: 179-194, 1988.
33. Maghazachi AA, Goldfarb RH and Herbernan RB: Influence of T cells on the expression of lymphokine-activated killer cell activity and in vivo tissue distribution. J Immunol 141: 4039-4046, 1988.
34. Basse PH, Nannmark U, Johansson R, Herberman RB, and Goldfarb RH: Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst 83: 944-950, 1991.
35. Basse BP, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, and Goldfarb RH: Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
36. Mule JJ, Yang JC, Lafreniere R, Shu S and Rosenberg SA: Indentification of cellular mechanisms operational in vivo during the regression of established pulmonary metastasis by the systemic administration of high-dose recombinant interleukin 2. J Immunol, 139: 285-294, 1987.
37. Weber JS, Jay G, Tanaka K and Rosenberg SA: Immunotherapy of a murine tumor with interleukin 2: Increased sensitivity after MHC Class I gene transfection. J Exp Med 166: 1716-1733, 1987.
38. Peace DJ and Cheever MA: Toxicity and therapeutic efficacy of high-dose interleukin 2: In vivo infusion of antibody to NK1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 169: 161-173, 1989.
39. Anderson TD, Hayes TJ, Gately MK, Botempo JM, Stern LL and Truitt GA: Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes: Seperation of efficacy and toxicity by selective lymphocyte subset depletion. Lab Invest 59: 598-612, 1988.
40. Gately MK, Anderson TD and Hayes TJ: Role of asailo-GMI-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol 141: 189-200, 1988.